South Korea
Every company in the roster headquartered in South Korea.
Every company in the roster headquartered in South Korea.
48 of 48 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Ahn-Gook Pharmaceutical001540 · KOSDAQ | 2 assets: 2 Ph 3 | AG2304Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | ~$14M |
Alteogen Inc.196170 · KOSDAQ | 1 asset: 1 other | Aflibercept (Eyluxvi)Age-Related Macular Degeneration | None on record | — | — | — | — |
Anterogen065660 · KOSDAQ | 1 asset: 1 Ph 2 | ALLO-ASCPhase 2 · Dystrophic Epidermolysis BullosaWeak signal | None on record | — | — | — | — |
AprilBio397030 · KOSDAQ | 1 asset: 1 Ph 2 | EVO301Phase 2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Aptabio Therapeutics293780 · KOSDAQ | 1 asset: 1 Ph 2 | IsuzinaxibPhase 2 · Type 2 DiabetesPartial signal | 30 Jun 2027Isuzinaxib · Phase 2 | — | — | — | — |
Boryung Pharmaceutical003850 · KOSPI | 1 asset: 1 Ph 3 | Fimasartan/atorvastatin/ezetimibe (BR1017)Phase 3 · HypertensionPartial signal | None on record | — | $170MMar 2026 | — | $38M |
Chong Kun Dang Pharmaceutical185750 · KOSPI | 9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 Ph 1 | CKD-701Phase 3 · Age-Related Macular DegenerationReliable signal | Dec 2029CKD-703 · Phase 1/2 | — | — | — | — |
Curacle365270 · KOSDAQ | 2 assets: 2 Ph 2 | CU01-1001Phase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
D&D Pharmatech347850 · KOSDAQ | 1 asset: 1 Ph 2 | ZabopegdutidePhase 2 · ObesityPartial signal | None on record | — | — | — | — |
Daewoong Pharmaceutical069620 · KOSPI | 7 assets: 4 Ph 3, 2 Ph 1, 1 other | EnavogliflozinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027Enavogliflozin · Phase 3 | — | — | — | $155M |
Dong-A ST170900 · KOSPI | 9 assets: 1 approved, 2 Ph 3, 2 Ph 2, 3 Ph 1, 1 other | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | Dec 2026DA-2811 · Phase 2 | — | — | — | — |
GemVax & KAEL082270 · KOSDAQ | 1 asset: 1 Ph 3 | TertomotidePhase 3 · Alzheimer's DiseasePartial signal | None on record | — | $15MMar 2026 | ~7.6 qtrs | ~$5.6M |
Handok002390 · KOSPI | 2 assets: 1 approved, 1 Ph 3 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hanmi Pharmaceutical128940 · KOSPI | 5 assets: 1 Ph 3, 3 Ph 2, 1 Ph 1 | efpeglenatidePhase 3 · ObesityReliable signal | Jan 2027HM15275 · Phase 2 | — | — | — | $161M |
HK inno.N Corporation195940 · KOSDAQ | 4 assets: 3 Ph 3, 1 Ph 2 | Amlodipine/valsartan/atorvastatin (CJ-30061)Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
HLB Life Science067630 · KOSDAQ | 2 assets: 2 Ph 3 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026Pyrotinib · Phase 1/2 | — | — | — | — |
Huons084110 · KOSDAQ | 1 asset: 1 Ph 1 | Liraglutide (HUC2-676)Phase 1 · Obesity | None on record | — | $134MDec 2025 | — | $47M |
IntoCell, Inc287840 · KOSDAQ | 1 asset: 1 Ph 1 | ITC-6146ROPhase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027ITC-6146RO · Phase 1 | — | — | — | — |
JW Pharmaceutical001060 · KOSPI | 7 assets: 5 Ph 3, 1 Ph 1, 1 other | AnagliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Mar 2027Anagliptin · Approved | — | — | — | $48M |
Kangstem Biotech217730 · KOSDAQ | 1 asset: 1 Ph 2 | Furestem-CDPhase 1/2 · Crohn's DiseaseWeak signal | None on record | — | — | — | — |
Kwang Dong Pharmaceutical009290 · KOSPI | 1 asset: 1 Ph 2 | bremelanotidePhase 2 · ObesityReliable signal | None on record | — | $98MDec 2025 | — | $6.4M |
LG Chem051910 · KOSPI | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027LB-LR1109 · Phase 1 | — | — | — | — |
LigaChem Biosciences, Inc.141080 · KOSDAQ | 2 assets: 1 Ph 2, 1 Ph 1 | LCB84Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027LCB84 · Phase 1/2 | — | — | — | — |
Mezzion Pharma140410 · KOSDAQ | 1 asset: 1 Ph 3 | UdenafilPhase 2/3 · Pulmonary Arterial HypertensionWeak signal | None on record | — | — | — | — |
Nature Cell Co., Ltd.007390 · KOSDAQ | 1 asset: 1 Ph 2 | AstroStemPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Peptron087010 · KOSDAQ | 1 asset: 1 Ph 2 | Exenatide (PT320)Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
ProGen296160 · KONEX | 2 assets: 1 Ph 2, 1 Ph 1 | PG-102Phase 2 · ObesityPartial signal | 1 Dec 2026RT-114 · Phase 1 | — | — | — | — |
Sam Chun Dang Pharm. Co., Ltd.000250 · KOSDAQ | 1 asset: 1 other | Aflibercept (Vgenfli)Age-Related Macular Degeneration | None on record | — | — | — | — |
Yuhan Corporation000100 · KOSPI | 7 assets: 1 approved, 1 Ph 3, 2 Ph 2, 3 other | SarpogrelatePhase 3 · Atherosclerotic Cardiovascular Disease | 31 Dec 2026Lazertinib · Phase 1 | — | $241MDec 2025 | — | — |
ABL BioPrivate | 1 asset: 1 Ph 2 | givastomigPhase 2 · Gastric Cancer | Dec 2026givastomig · Phase 1 | — | — | — | — |
AddpharmaPrivate | 3 assets: 1 Ph 3, 1 Ph 1, 1 other | AD-209Phase 3 · HypertensionPartial signal | None on record | — | — | — | — |
AJU PharmPrivate | 2 assets: 2 Ph 3 | Valsartan/amlodipine/chlorthalidone (AJU-C52)Phase 3 · HypertensionReliable signal | None on record | — | — | — | — |
AriBioPrivate | 1 asset: 1 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
BCWorld PharmPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
BeyondBioPrivate | 1 asset: 1 Ph 2 | BEY2153Phase 2 · Alzheimer's DiseasePartial signal | Jul 2028BEY2153 · Phase 2 | — | — | — | — |
BnH Research (Korea)Private | 1 asset: 1 Ph 1 | BnH-015BPhase 1 · Alzheimer's Disease | None on record | — | — | — | — |
CKD Bio CorporationPrivate | 1 asset: 1 other | L. lactis CKDB001Alzheimer's Disease | 31 May 2027L. lactis CKDB001 · Phase na | — | — | — | — |
G2GBio, Inc.Private | 1 asset: 1 Ph 1 | GB-5001Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
GlaceumPrivate | 1 asset: 1 Ph 2 | VutiglabridinPhase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Innovo TherapeuticsPrivate | 1 asset: 1 Ph 1 | INV-101Phase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
J Ints BioPrivate | 1 asset: 1 Ph 2 | JIN-A02Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Jeil PharmaceuticalPrivate | 1 asset: 1 Ph 3 | Pioglitazone (JT-001)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Lmito TherapeuticsPrivate | 1 asset: 1 Ph 1 | LMT503Phase 1 · Ulcerative Colitis | 1 Sep 2027LMT503 · Phase 1 | — | — | — | — |
Mediforum Ltd., Co.Private | 1 asset: 1 Ph 3 | PM012Phase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
NEUROBiOGENPrivate | 1 asset: 1 Ph 2 | TisolagilinePhase 2 · Obesity | 31 Jan 2027Tisolagiline · Phase 2 | — | — | — | — |
PharmacobioPrivate | 1 asset: 1 Ph 1 | DDN-A-0101Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Twinpig Biolab, Inc.Private | 1 asset: 1 Ph 2 | TB511Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027TB511 · Phase 1/2 | — | — | — | — |
VTBIO Co. Ltd (South Korea)Private | 1 asset: 1 Ph 1 | VT301Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.